CureVac N.V.

NASDAQ:CVAC

4.47 (USD) • At close May 30, 2025
Bedrijfsnaam CureVac N.V.
Symbool CVAC
Munteenheid USD
Prijs 4.47
Beurswaarde 1,006,447,320
Dividendpercentage 0%
52-weken bereik 2.37 - 5.28
Industrie Biotechnology
Sector Healthcare
CEO Dr. Alexander Zehnder M.B.A., M.D.
Website https://www.curevac.com

An error occurred while fetching data.

Over CureVac N.V.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial

Vergelijkbare Aandelen

Blueprint Medicines Corporation logo

Blueprint Medicines Corporation

BPMC

101.35 USD

Cytokinetics, Incorporated logo

Cytokinetics, Incorporated

CYTK

31.02 USD

Inari Medical, Inc. logo

Inari Medical, Inc.

NARI

79.97 USD

Merit Medical Systems, Inc. logo

Merit Medical Systems, Inc.

MMSI

95.03 USD

Ultragenyx Pharmaceutical Inc. logo

Ultragenyx Pharmaceutical Inc.

RARE

34.03 USD

Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

NTLA

6.87 USD

Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc.

MRTX

58.7 USD

Natera, Inc. logo

Natera, Inc.

NTRA

157.73 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)